Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Depreciation and Depletion: 2015-2024

Historic Depreciation and Depletion for Axsome Therapeutics (AXSM) over the last 10 years, with Dec 2024 value amounting to $532,000.

  • Axsome Therapeutics' Depreciation and Depletion fell 8.40% to $120,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $518,000, marking a year-over-year decrease of 3.36%. This contributed to the annual value of $532,000 for FY2024, which is 15.90% up from last year.
  • According to the latest figures from FY2024, Axsome Therapeutics' Depreciation and Depletion is $532,000, which was up 15.90% from $459,000 recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Depreciation and Depletion registered a high of $532,000 during FY2024, and its lowest value of $23,864 during FY2020.
  • For the 3-year period, Axsome Therapeutics' Depreciation and Depletion averaged around $418,000, with its median value being $459,000 (2023).
  • Per our database at Business Quant, Axsome Therapeutics' Depreciation and Depletion slumped by 36.07% in 2020 and then soared by 246.05% in 2022.
  • Yearly analysis of 5 years shows Axsome Therapeutics' Depreciation and Depletion stood at $23,864 in 2020, then spiked by 218.47% to $76,000 in 2021, then soared by 246.05% to $263,000 in 2022, then skyrocketed by 74.52% to $459,000 in 2023, then rose by 15.90% to $532,000 in 2024.